Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential

June 3, 2026 9:02 AM

Benchmark analyst Robert Wasserman reiterated a Buy rating and $90.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found